The Semaglutide 3 mg Tablet: What It Is, What It Isn't

Step 1, Recognise which oral semaglutide product you are looking at

Semaglutide comes in two distinct oral medicines in the UK. The older one is Rybelsus, introduced for adults with type 2 diabetes; its tablet strengths are 3 mg, 7 mg and 14 mg. The 3 mg tablet is purely a starter dose for diabetes management, prescribed at the beginning of Rybelsus treatment to help the body adjust before the therapeutic 7 mg or 14 mg doses are reached. It has no licensed role in weight management and no evidence base for that use.

The newer product is Wegovy tablets, the same molecule, semaglutide, but formulated at higher concentrations alongside an absorption enhancer called SNAC, and studied specifically in people living with obesity. If you have been searching for a semaglutide tablet to help with weight, Wegovy tablets are the medicine the MHRA has licensed for that purpose. The 1.5 mg starting dose of Wegovy tablets is the point where that journey begins, not 3 mg.

The practical upshot: a 3 mg semaglutide tablet dispensed for weight loss would be the wrong product, at the wrong dose, under the wrong licence. Any prescriber offering it in that context would be prescribing outside the medicine's authorised indication.

Step 2, Follow how the Wegovy tablet dose actually progresses

The Wegovy tablet schedule moves in four steps, each lasting a minimum of one month before the prescriber considers moving up. It opens at 1.5 mg, advances to 4 mg, then 9 mg, and reaches the 25 mg maintenance dose. Patients who are already established on the 2.4 mg weekly Wegovy injection may transition directly to the 25 mg tablet, though that switch is always subject to a clinical assessment. You can read more about how the Wegovy tablet dosing schedule works in full detail.

None of those four rungs (1.5 mg, 4 mg, 9 mg, 25 mg) corresponds to 3 mg, 7 mg or 14 mg. If a source lists those numbers as Wegovy tablet doses, it is conflating the two products. The full breakdown of semaglutide tablet doses sets out which numbers belong to which product and why the distinction matters clinically.

One practical point worth knowing: Wegovy tablets must be taken first thing in the morning on an empty stomach, swallowed whole with no more than a small amount of plain water, then a wait of at least 30 minutes before anything else, food, coffee or other oral medicines. Food and drink too soon after the tablet significantly reduces how much semaglutide the body absorbs. No refrigeration is needed, which makes the tablet format genuinely convenient for travel and daily routines.

Step 3, Understand the evidence behind the tablet form

Phase 3 trial data for Wegovy tablets (the OASIS 4 study, 307 adults with obesity or overweight plus at least one weight-related condition, 64 weeks) showed an average weight reduction of approximately 13.6% compared with around 2.4% for placebo, alongside lifestyle changes. Among participants who stayed fully adherent to treatment throughout, average weight loss reached approximately 16 to 17%. The page on semaglutide and the 3 mg question in a weight-loss context goes deeper on why the Rybelsus 3 mg strength cannot be extrapolated to these results.

The MHRA's approval of Wegovy tablets covers adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes, used alongside a reduced-calorie diet and increased physical activity. The medicine carries the Black Triangle symbol (▼), meaning it is subject to additional monitoring. Suspected side effects can be reported at the MHRA Yellow Card scheme. For a thorough overview of the tablet's approval and what it covers, the guide to oral semaglutide dosing for weight loss is a useful next read.

Wegovy tablets are not available on the NHS at the time of writing, a NICE appraisal would be required before NHS commissioning could begin. That means private prescription is currently the only route. For context on what private oral semaglutide treatment costs, the Wegovy tablet price page sets out what a legitimate prescription typically includes.

Side effects to be aware of with oral semaglutide

The side-effect profile of Wegovy tablets is broadly similar to the injection, though gastrointestinal effects were more common in the OASIS 4 trial than with the injectable form: around 74% of tablet users reported GI symptoms versus 42% of those on placebo. Nausea, diarrhoea, constipation, vomiting and indigestion are the most frequently reported. Most are mild to moderate and tend to ease as the body adjusts after starting or after a dose increase.

Rare but serious events (including acute pancreatitis) are flagged in the product information. If you experience severe stomach pain that spreads toward the back, with or without vomiting, seek urgent medical attention. The NHS semaglutide information page covers when to get help and what to watch for across the semaglutide medicines. Wegovy tablets are not recommended during pregnancy, breastfeeding or when actively trying to conceive, and they are not licensed for anyone under 18. These are conversations for a prescriber, not something to assess alone. Our clinical team reviews every consultation individually and can answer questions specific to your situation.

If you are ready to explore whether Wegovy tablets or another licensed weight-loss treatment suits you, start your free consultation and a GPhC-registered prescriber will review it the same day.